DOCSLIB.ORG

United States District Court for the Southern District of New York

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States District Court for the Southern District of New York Case 1:17-cv-03960-JMF Document 85 Filed 05/29/18 Page 1 of 3 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK CHARLES SEIFE, Plaintiff, v. FOOD AND DRUG ADMINISTRATION and Case No. 1:17-cv-3960 (JMF) DEPARTMENT OF HEALTH AND HUMAN SERVICES, Defendants, ORAL ARGUMENT and REQUESTED SAREPTA THERAPEUTICS, Intervenor-Defendant. May 29, 2018 NOTICE OF CROSS-MOTION FOR SUMMARY JUDGMENT PLEASE TAKE NOTICE that upon the annexed memorandum of law; supporting declarations of Cortelyou Kenney, Charles Seife, Dr. Peter Lurie, Dr. Diana Zuckerman, and the exhibits appended thereto; Local Rule 56.1 statement of undisputed material facts and response to Sarepta’s statement of undisputed material facts; and all prior pleadings and proceedings herein, Plaintiff Charles Seife moves this Court for summary judgment on the issue of the merits of defendants’ withholdings under the Freedom of Information Act (FOIA)’s Exemption 4. As more fully set forth in the memorandum, Seife seeks an order declaring that the de- identified clinical trial information described in Exhibit A to the Kenney Declaration that Seife seeks is not exempt and should be produced by defendants, and for any further relief to which Seife may be entitled. In the alternative, to the extent the Court finds the defendants’ claims have merit, Seife Case 1:17-cv-03960-JMF Document 85 Filed 05/29/18 Page 2 of 3 respectfully seeks in camera review of the information and segregation of exempt from non-exempt information, as discussed in his annexed memorandum of law, and any other relief the Court deems just and proper. Dated: May 29, 2018 New York, NY Respectfully Submitted, MEDIA FREEDOM & INFORMATION ACCESS CLINIC By: /s/Cortelyou Kenney Thomas S. Leatherbury Cortelyou C. Kenney Daniel L. Tobey David A. Schulz Vinson & Elkins Jeanie Kim 2001 Ross Avenue, Suite 3700 Anna Windemuth, Law Student Intern Dallas, TX 75201 Shannon Price, Law Student Intern Tel: (214) 220-7792 Abigail McCourt, Law Student Intern [email protected] Abrams Institute for Freedom of [email protected] Expression Yale Law School Devon C. Holstad PO Box 208215 Sarah Tishler New Haven, CT 06520 Vinson & Elkins Tel: (203) 432-4366 666 Fifth Avenue, 26th Floor [email protected] New York, NY 10103 [email protected] Tel: (212) 237-0000 [email protected] [email protected] [email protected] 2 Case 1:17-cv-03960-JMF Document 85 Filed 05/29/18 Page 3 of 3 Certificate of Service On May 29, 2018, a copy of the foregoing document was served on all counsel of record via the Court’s Electronic Case Filing (ECF) system. By: /s/Cortelyou Kenney One of Counsel 3 Case 1:17-cv-03960-JMF Document 86 Filed 05/29/18 Page 1 of 58 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK CHARLES SEIFE, Plaintiff, v. FOOD AND DRUG ADMINISTRATION and Case No. 1:17-cv-3960 (JMF) DEPARTMENT OF HEALTH AND HUMAN SERVICES, Defendants, and SAREPTA THERAPEUTICS, Intervenor-Defendant. May 29, 2018 COMBINED MEMORANDUM IN OPPOSITION TO DEFENDANTS’ MOTIONS FOR SUMMARY JUDGMENT AND IN SUPPORT OF PLAINTIFF’S CROSS-MOTION FOR SUMMARY JUDGMENT Cortelyou C. Kenney Thomas S. Leatherbury David A. Schulz Daniel L. Tobey Jeanie Kim Vinson & Elkins Anna Windemuth, Law Student Intern 2001 Ross Avenue, Suite 3700 Shannon Price, Law Student Intern Dallas, TX 75201 Abigail McCourt, Law Student Intern Tel: (214) 220-7792 Media Freedom & Information [email protected] Access Clinic [email protected] Abrams Institute for Freedom of Expression Devon C. Holstad Yale Law School Sarah Tishler P.O. Box 208215 Vinson & Elkins New Haven, CT 06520 666 Fifth Avenue, 26th Floor Tel: (203) 432-4366 New York, NY 10103 [email protected] Tel: (212) 237-0000 [email protected] [email protected] [email protected] [email protected] Counsel for Plaintiff Charles Seife ORAL ARGUMENT REQUESTED Case 1:17-cv-03960-JMF Document 86 Filed 05/29/18 Page 2 of 58 TABLE OF CONTENTS TABLE OF AUTHORITIES ......................................................................................................................... iv PRELIMINARY STATEMENT .................................................................................................................... 1 STATEMENT OF FACTS .............................................................................................................................. 2 A. The CSR Safety and Efficacy Information at Issue......................................................................... 2 B. The Controversy Surrounding the Approval of Exondys 51 ........................................................ 4 C. Background to This Lawsuit and Procedural History ..................................................................... 7 D. Information Already Learned Through Defendants’ FOIA Response ........................................ 8 1. Concerns about the FDA approval process ....................................................................... 8 2. Evidence of the possible manipulation of study results.................................................. 10 E. The Pending Cross-Motions ............................................................................................................. 11 ISSUES PRESENTED AND STANDARD OF REVIEW .................................................................... 11 ARGUMENT ................................................................................................................................................... 13 I. DEFENDANTS FAIL TO DEMONSTRATE ANY PROPER BASIS FOR WITHHOLDING SAREPTA’S CSR INFORMATION UNDER EXEMPTION 4................................................................................................................................. 13 A. Defendants Bear A Heavy Burden to Withhold CSR Information That Inherently Informs About Both FDA Activity and Drug Safety and Effectiveness ......................................................................................................................... 13 B. Defendants Fail To Establish That Disclosing The CSR Information Would Cause Substantial Competitive Harm ................................................................... 17 1. Defendants’ conclusory contentions are insufficient to establish substantial and imminent competitive harm ....................................................... 17 2. So much information about approved drugs must be disclosed by law that any incremental competitive harm from disclosing the CSR information would not be substantial................................................... 22 (a) Much of the drug efficacy data contained in CSRs must be made public through ClinicalTrials.gov and FDA Advisory Committee materials and is routinely disclosed in scientific publications ........................................................................... 24 i Case 1:17-cv-03960-JMF Document 86 Filed 05/29/18 Page 3 of 58 (b) Much of the adverse event and safety data contained in the CSRs must be made public through ClinicalTrials.gov and FDA Advisory Committee materials and is routinely disclosed in scientific publications .......................................................... 26 3. The unsubstantiated claims of harm by Sarepta and the FDA do not withstand scrutiny ............................................................................................ 27 (a) Defendants have not established that the redacted CSR information would be of any material use to a Sarepta competitor .................................................................................................. 28 (i) Study procedures .......................................................................... 29 (ii) Study results .................................................................................. 30 (iii) Exploratory endpoints ................................................................ 32 (iv) Adverse events ............................................................................. 32 (b) Defendants have not established that Sarepta faces an imminent competitive injury if the withheld CSR information is disclosed ............................................................................ 34 C. Sarepta Fails To Demonstrate That Disclosing The CSR Information Will Impair The FDA’s Ability To Regulate, Which The FDA Implicitly Concedes ................................................................................................................................ 35 D. An Overwhelming Public Interest Warrants Disclosure Of Sarepta’s CSR Information .................................................................................................................. 36 1. CSR information will inform about the actions of the FDA............................ 36 (a) The CSR information will shed light on whether the FDA is complying with statutory requirements .................................... 36 (b) The CSR information will shed light on whether the FDA approved an “elegant placebo” through a process infected by misconduct ............................................................................. 39 2. The withheld CSR information is needed to understand and evaluate the safety of Exondys 51 ........................................................................ 42 3. The withheld CSR information is also relevant to insurance companies’ coverage decisions and physicians’ prescription practices .................................................................................................................... 44 II. IN THE ALTERNATIVE, DEFENDANTS HAVE NOT REASONABLY
Load more

Recommended publications
  • Breast Implants: Choices Women Thought They Made
    NYLS Journal of Human Rights Volume 11 Issue 1 Article 5 Fall 1993 BREAST IMPLANTS: CHOICES WOMEN THOUGHT THEY MADE Zoe Panarites Follow this and additional works at: https://digitalcommons.nyls.edu/journal_of_human_rights Part of the Law Commons Recommended Citation Panarites, Zoe (1993) "BREAST IMPLANTS: CHOICES WOMEN THOUGHT THEY MADE," NYLS Journal of Human Rights: Vol. 11 : Iss. 1 , Article 5. Available at: https://digitalcommons.nyls.edu/journal_of_human_rights/vol11/iss1/5 This Notes and Comments is brought to you for free and open access by DigitalCommons@NYLS. It has been accepted for inclusion in NYLS Journal of Human Rights by an authorized editor of DigitalCommons@NYLS. BREAST IMPLANTS: CHOICES WOMEN THOUGHT THEY MADE Nearly two million women- received breast implants between 1962 and 1991: eighty percent for cosmetic purposes, and twenty percent for reconstructive surgery following mastectomies. 1 From their inauspicious beginnings as a tool for Japanese prostitutes during World War II to enlarge their breasts for American servicemen, 2 implants have now been deemed crucial to post-mastectomy recipients3 and other women seeking self-improvement." Implants are © Copyright 1993 by the New York Law School Journalof Human Rights. 'John R. Easter ct al., Medical "State of the Art"for the Breast Implant Litigation, in BREAST IMPLANT Lrrio. 1, 12 (Law Journal Seminars-Press 1992). This Note will focus primarily on silicone-filled implants. Food and Drug Administration ("FDA") estimates released in 1988 indicate that only 15% of implant surgeries were for reconstructive purposes, while 85% were for cosmetic purposes. Teich v. FDA, 751 F. Supp. 243, 245-46 (D.D.C.
    [Show full text]
  • Spring/Summer 2019
    34 We are dedicated to improving the health and How Can We Cut the Cost of Medical Care? safety of adults and children by using research to develop Everyone agrees that health insurance is too Our own research on cancer drugs found that expensive and prescription drugs cost much too many that were recently approved based on their more effective treatments and much – some cost more than patients’ annual success at shrinking tumors provided zero benefit income! The amount Americans spend on to the average patient in terms of living longer or policies. The Cancer prescription drugs has nearly doubled since the having a better quality of life. Since cancer drugs Prevention and Treatment 1990s, and today the most expensive drugs cost so often cause nausea, vomiting, exhaustion, and $500,000 or more per year. other debilitating side effects, it is unconscionable Fund is our major program. that these drugs are being approved without clear What’s the solution? evidence that they work – or which patients have at least some chance of benefitting even if most This article isn’t about Medicare for All, Medicaid don’t. for All, or other major legislation, all of which face enormous political and corporate opposition. Instead, this article focuses on the issues that would be easier to fix in the near term. How to Spend Less on Drugs and Medical Tests Too many patients are being priced out of the Our Cancer Prevention and medical treatment that they need – or think they Treatment Fund helps adults need. As prices have risen, companies have broken one record after another, so that it seems there is and children reduce their risk no limit on what they will charge.
    [Show full text]
  • Fall 2018/Winter 2019
    ISSUE ISSUE 2433 TheTheVoice Voice FALL/WINTER 2018 FOR PREVENTION, TREATMENT, AND POLICY SPRING/SUMMER 2014 FOR PREVENTION, TREATMENT, AND POLICY National WHAT’S INSIDE We’re in the Headlines…2 Center Brain Stimulation as a Treatment for Depression?...3 What are the Implant Files?...4 for Health Is the Affordable Care Act Still at Risk?....4 What is Breast Implant Illness?...5 Research Honoring Foremothers….6 Dietary Supplements...7 We are dedicated to improving the health and safety of adults and children by Can Sleeping Pills Cause Cancer? Can Avoiding using research to develop more Them Improve Your Health? effective treatments and policies. The Cancer Americans spend more than $41 billion each year on prescription sleeping pills, and that doesn’t Prevention and Treatment count the popular over-the-counter sleep aids such Fund is our major program. as Tylenol PM and Benadryl. If you are one of the many Americans that needs help sleeping, you’ll want to know about a study showing that people who take these drugs are significantly more likely to be diagnosed with cancer or to die within the next The Cancer two and a half years than people who don’t take Even before this study, there were at least 18 other them. Published in the prestigious British Medical studies showing an increased risk of death for Prevention Journal, author Dr. Daniel Kripke estimates that people taking sleeping pills, and several also and Treatment sleep medications could be causing more than showed an increased risk of cancer. However, this Fund 300,000-500,000 deaths every year.
    [Show full text]
  • Implications for Patients and Health Policy Conference Agenda
    What Evidence is Essential for New Medical Products? Implications for Patients and Health Policy June 13, 2014 AAAS Headquarters Washington, DC Conference Agenda 8:00 am Registration 8:30 am Welcome Remarks: Mark S. Frankel American Association for the Advancement of Science 8:40 am Keynote Addresses Introductions: Diana Zuckerman National Center for Health Research 8:45 am Remarks: Congresswoman Rosa L. DeLauro (D-CT) 9:05 am Remarks: Margaret R. Hamburg (via live video) Food & Drug Administration 9:15 am Panel I. Evidence-Based Policy: Opportunities and Challenges Moderator: Susan F. Wood George Washington University Speakers: Aaron S. Kesselheim Brigham and Women’s Hospital/Harvard Medical School Robert Yarchoan National Cancer Institute Gregory D. Curfman New England Journal of Medicine Rita F. Redberg JAMA Internal Medicine 10:45 am Panel II. Speed vs. Safety: Implications for Public Health of Changing Standards for Getting Products to Market Moderator: Kim Witczak Patient Safety Advocate Speakers: Bernard Lo Greenwall Foundation Lisa M. Schwartz & Steven Woloshin Dartmouth Medical School Michael Rosenblatt Merck 12:00 pm Lunch 1:00 pm Panel III. Biomarkers, Surrogate Endpoints and Other Shortcuts that May or May Not Predict Health Outcomes Moderator: Thomas J. Moore Institute for Safe Medication Practices Speakers: Jerry Avorn Brigham and Women’s Hospital/Harvard Medical School Joseph S. Ross Yale School of Medicine Diana Zuckerman National Center for Health Research Ann de Velasco WomenHeart of Miami 2:30 pm Panel IV. Post-Market Surveillance and Comparative Effectiveness Research Moderator: Tianjing Li Johns Hopkins University Speakers: Robert Ball Food & Drug Administration Sebastian Schneeweiss Brigham and Women’s Hospital/Harvard Medical School Patrick Ryan Janssen Research and Development 3:45 pm Break 4:00 pm Panel V.
    [Show full text]
  • Long Term Effects of Dab Pens
    Long Term Effects Of Dab Pens Heavy-handed Corrie louts indestructibly. Is Woodrow culicid or semiparasitic after cotemporaneous mimicsTheo automobiles very vaingloriously so sycophantically? and spryly? Is Cole always theism and geochemical when cooperated some In design and long term This field is created when you smoked, also find the aerosol is the pipe and general categories: an fda approval that a breakdown in. But, the truth no the felt is that individuals would not recover the symptoms of withdrawal if there now nothing to disperse from. What boss a cannabis dab pen Leafly. Is Vaping Bad play You Vaping vs Smoking Side Effects and. Weed vapes What you need to make about marijuana CNET. Learn learn the research. Like many vaping products, different batteries provide varying functions and are compatible with disease other products. Another person realized he is dabbing temperatures needed a long run low and effects that cbd and dependence: which contains no. Publications and Reports of the Surgeon General. Early reactions to dab pens. Dna damage to list of? This includes the script as async. Are and aware, has there enough people, companies and bloggers who override their entire days unraveling these lies and exposing the truth lend them? Very friendly but helpful ready with vast product knowledge. Our comments here to not intended it a diatribe against vaping or the legalization of cannabis. It whereas Black Note. The Mighty is no portable powerhouse. Diana zuckerman and. You could probably do consent better. Medical staff revise the depth in Miami, where she as been airlifted, struggled to keep anyone alive.
    [Show full text]
  • John Allen Paulos Curriculum Vitae – 2016
    (Note: This C.V. was originally compiled to conform to a University form, which, like most such institutional templates, is repetitive, clunky, and a little lacking in narrative verve. On the other hand, it is a C.V. and not an autobiography. (For that see my new book - Nov., 2015 – A Numerate Life.) More about me is available on my website at www.math.temple.edu/paulos) John Allen Paulos Curriculum Vitae – 2016 Education, Academic Position: Education: Public Schools, Milwaukee; B.S., University of Wisconsin, Madison, 1967; M.S., University of Washington, 1968; U.S. Peace Corps, 1970; Ph. D. in mathematics, University of Wisconsin, Madison, 1974. Doctoral Dissertation: "Delta Closed Logics and the Interpolation Property"; 1974; Professor K. Jon Barwise. Positions Held: Temple University Mathematics Department: 1973, Assistant Professor, 1982, Associate Professor, 1987, Full Professor Columbia University School of Journalism 2001, Visiting Professor Nanyang Technological University, summer visitor, 2011-present Awards: My books and expository writing as well as my public talks and columns led to my receiving the 2003 Award for promoting public understanding of science from the American Association for the Advancement of Science. (Previous winners include Carl Sagan, E. O. Wilson, and Anthony Fauci.) I received the 2002 Faculty Creative Achievement Award from Temple University for my books and other writings. My piece "Dyscalculia and Health Statistics" in DISCOVER magazine won the Folio Ovation Award for the best piece of commentary in any American magazine. My books and expository writing as well as my public talks and columns also led to my receiving the 2013 Mathematics Communication Award from the Joint Policy Board of 1 Mathematics.
    [Show full text]
  • INSTITUTION Congress of the US, Washington, DC. House Committee
    DOCUMENT RESUME ED 303 136 IR 013 589 TITLE Commercialization of Children's Television. Hearings on H.R. 3288, H.R. 3966, and H.R. 4125: Bills To Require the FCC To Reinstate Restrictions on Advertising during Children's Television, To Enforce the Obligation of Broadcasters To Meet the Educational Needs of the Child Audience, and for Other Purposes, before the Subcommittee on Telecommunications and Finance of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress (September 15, 1987 and March 17, 1988). INSTITUTION Congress of the U.S., Washington, DC. House Committee on Energy and Commerce. PUB DATE 88 NOTE 354p.; Serial No. 100-93. Portions contain small print. AVAILABLE FROM Superintendent of Documents, Congressional Sales Office, U.S. Government Printing Office, Washington, DC 20402. PUB TYPE Legal/Legislative/Regulatory Materials (090) -- Viewpoints (120) -- Reports - Evaluative/Feasibility (142) EDRS PRICE MFO1 /PC15 Plus Postage. DESCRIPTORS *Advertising; *Childrens Television; *Commercial Television; *Federal Legislation; Hearings; Policy Formation; *Programing (Broadcast); *Television Commercials; Television Research; Toys IDENTIFIERS Congress 100th; Federal Communications Commission ABSTRACT This report provides transcripts of two hearings held 6 months apart before a subcommittee of the House of Representatives on three bills which would require the Federal Communications Commission to reinstate restrictions on advertising on children's television programs. The texts of the bills under consideration, H.R. 3288, H.R. 3966, and H.R. 4125 are also provided. Testimony and statements were presented by:(1) Representative Terry L. Bruce of Illinois; (2) Peggy Charren, Action for Children's Television; (3) Robert Chase, National Education Association; (4) John Claster, Claster Television; (5) William Dietz, Tufts New England Medical Center; (6) Wallace Jorgenson, National Association of Broadcasters; (7) Dale L.
    [Show full text]
  • Introduction Fact Checking
    Innovative Health Solutions’ Response to NPR Story: Questions Raised About Study of Device to Ease Opioid Withdrawal Introduction Jake Harper’s NPR story, Questions Raised About Study of Device to Ease Opioid Withdrawal, presented a biased and misleading view of the NSS-2 BRIDGE device. To address his story’s factual inaccuracies, this document provides a comparison to many of Harper’s claims with facts backed by the IHS team and its research. Fact Checking Inaccuracy: Innovative Health Solutions (IHS), the device maker, has marketed the BRIDGE for opioid withdrawal for more than a year, even before it had clearance for that use from the Food and Drug Administration. Fact: IHS did not market the BRIDGE for opioid withdrawal prior to FDA clearance. The original 510(k)-cleared BRIDGE device was indicated for use in the acute and chronic pain population. Pain is highly prevalent in this patient population, which led some clinicians to adopt in their treatment of patients. Subsequently, IHS received clearance for a next generation product – the NSS-2 BRIDGE – with a claim that it could reduce the symptoms of opioid withdrawal. What Mr. Harper may be referring to, and what he asked IHS about previously, were conversations with policymakers in a non-promotional setting about future applications for IHS technology. In that context, as we explained to Mr. Harper, IHS has every right to discuss ongoing development and future activities, but Mr. Harper chose to ignore our input. Inaccuracy: An investigation by Side Effects Public Media and NPR reveals that researchers working with Innovative Health Solutions, maker of the BRIDGE, submitted to a medical journal a study that wasn't what it appeared to be.
    [Show full text]
  • You Might Be a Robot
    \\jciprod01\productn\C\CRN\105-2\CRN203.txt unknown Seq: 1 28-MAY-20 13:27 YOU MIGHT BE A ROBOT Bryan Casey† & Mark A. Lemley‡ As robots and artificial intelligence (AI) increase their influ- ence over society, policymakers are increasingly regulating them. But to regulate these technologies, we first need to know what they are. And here we come to a problem. No one has been able to offer a decent definition of robots and AI—not even experts. What’s more, technological advances make it harder and harder each day to tell people from robots and robots from “dumb” machines. We have already seen disas- trous legal definitions written with one target in mind inadver- tently affecting others. In fact, if you are reading this you are (probably) not a robot, but certain laws might already treat you as one. Definitional challenges like these aren’t exclusive to robots and AI. But today, all signs indicate we are approaching an inflection point. Whether it is citywide bans of “robot sex brothels” or nationwide efforts to crack down on “ticket scalp- ing bots,” we are witnessing an explosion of interest in regu- lating robots, human enhancement technologies, and all things in between. And that, in turn, means that typological quandaries once confined to philosophy seminars can no longer be dismissed as academic. Want, for example, to crack down on foreign “influence campaigns” by regulating social media bots? Be careful not to define “bot” too broadly (like the California legislature recently did), or the supercomputer nes- tled in your pocket might just make you one.
    [Show full text]
  • Is a COVID-19 Vaccine a Good Idea for You? Will Your Life Children by Using Research Go Back to Normal? to Develop More Effective Treatments and Policies
    36 We are dedicated to improving the health and safety of adults and Is a COVID-19 Vaccine a Good Idea for You? Will Your Life children by using research Go Back to Normal? to develop more effective treatments and policies. If you are at high risk of COVID-19 because you are The Cancer Prevention older, have cancer or other serious diseases, or even if you’re at average risk, you’re probably wondering and Treatment Fund is our if you should get a vaccine as soon as possible. As major program. we write this, there is not yet a COVID-19 vaccine that is widely available. But, we have preliminary data about some of the vaccines. The goal of this article is to give you the information you need to help you make an informed decision. We will also try to answer this key question: Will the vaccines be good enough so that life goes back to normal? On October 22, the FDA held a public Advisory gotten the vaccine. That sounds very impressive. Committee meeting to discuss the scientific However, these studies must continue and it could standards needed for a COVID-19 vaccine to be be many months before the studies can conclude Our Cancer Prevention considered good enough to be sold. Food and Drug whether the vaccines prevent hospitalizations or and Treatment Fund helps Administration (FDA) approval standards are deaths of the people most at risk. And it could be higher than the standards for FDA’s “Emergency much longer before we know if people taking either adults and children reduce Use Authorization” (EUA).
    [Show full text]
  • Biennial Report 2018-19
    Cancer Prevention and Treatment Fund A voice you can trust in prevention, treatment, and policy Biennial Report 2018-2019 2 MESSAGE FROM THE PRESIDENT We persuaded Congress to proven accurate and secure for protect all Americans’ access to all patients. affordable health insurance, We trained and continue to including those with pre- work with 100 patient existing conditions such as advocates from across the cancer. country on how to make their We trained researchers and voices heard to improve journalists to better medical research on cancer communicate the results of treatments and prevention. research on which treatments We updated our free booklet are best for which patients, and for women with ductal publicized important new study carcinoma in situ (DCIS) and results. our free booklet for men about We urged the Food and Drug prostate cancer screening. We In 2018 and 2019, we helped Administration (FDA) to made both booklets widely thousands of adults and children require long-term studies of the available to patients and family get the best possible medical treat- safety and effectiveness for all members across the country. ment; we published articles and medications, implants, and Whether we were explaining well- reports that will continue to help vaccines, so that consumers physicians provide better medical established and complicated could make well-informed treatment; and we had a major im- medical research information to decisions for themselves and pact on the many invisible govern- families and health professionals, ment policies that can reduce or their children. or making sense of controversial new research on vaccines, increase our risk of cancer.
    [Show full text]
  • Spring/Summer 2017 for Prevention, Treatment, and Policy Spring/Summer 2014 for Prevention, Treatment, and Policy
    ISSUE ISSUE 2430 TheTheVoiceVoice SPRING/SUMMER 2017 FOR PREVENTION, TREATMENT, AND POLICY SPRING/SUMMER 2014 FOR PREVENTION, TREATMENT, AND POLICY WHAT’S INSIDE National We’re in the Headlines…2 Antipsychotics & Young Kids: How Safe are They?...3 Center Making Our Voices Heard...4 for Health Matching Game for Medications...5 Research Right to Try? Or Right to be Exploited Before You Die?...6 We are dedicated to improving the health and Which Sunscreens Offer the Best Protection? safety of adults and children We all need 15 minutes of sunshine every day to by using research to develop benefit from vitamin D. Otherwise, staying out of the sun is important to prevent skin more effective treatments cancer. But, let’s face it, the sun feels good! In and policies. The Cancer addition to avoiding sun exposure in the hours Prevention and Treatment around noon, especially during the summer, sunscreen can also help protect you and yours Fund is our major program. from some of the damaging effects of the sun. But what kind of sunscreen is best? Spray or lotion? SPF 15 or SPF 70? Waterproof or moisturizing? It seems like new rules come out The Cancer every year. kids into the routine of applying sunscreen every Prevention and And it is important to know that the Food and morning (after they brush their teeth) before Treatment Fund Drug Administration (FDA) has never required going to school or to camp, no matter how cloudy sunscreens to be proven to prevent skin it is outside. But remember, they will need to add Our Cancer Prevention and cancer.
    [Show full text]